IMVT

IMVT R&D Expenses

$498.09MTTM · USD

Period ending:

IMVT FY R&D ExpensesUSD
IMVT FY R&D Expenses2018-03-31: $135.26M2019-03-31: $25.73M2020-03-31: $47.93M2021-03-31: $68.60M2022-03-31: $101.81M2023-03-31: $160.26M2024-03-31: $212.93M2025-03-31: $360.92M2026-03-31: $456.66M$456.66M$0.00
2018-03-312026-03-31

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

IMVT r&d expenses history

Research and development spending. The available annual fiscal periods series contains 9 observations from Mar 31, 2018 to Mar 31, 2026.

Immunovant Inc R&D Expenses — Annual fiscal periods (USD)
Period endingR&D Expenses (USD)
456,660,000
360,917,000
212,928,000
160,257,000
101,808,000
68,604,000
47,927,000
25,733,000
135,263,000

Compare r&d expenses

All IMVT financial metrics · IMVT stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.